Question 1

What are lipid nanoparticles (LNPs)?

Accepted Answer

Lipid nanoparticles are microscopic delivery systems that act like courier services, safely transporting delicate genetic instructions into human cells. They're the unsung heroes of the mRNA revolution, making COVID-19 vaccines and gene therapies possible by protecting therapeutic molecules from the body's natural defences.

Question 2

Why did Moderna pay £2.25 billion for LNP patents?

Accepted Answer

Moderna's massive settlement with Arbutus Biopharma and Genevant Sciences demonstrates that delivery technology is extraordinarily valuable. Without LNP patents, Moderna's £36 billion COVID vaccine success wouldn't have been possible—the settlement validates delivery systems as potentially more valuable than the drugs themselves.

Question 3

What is platform investing in biotech?

Accepted Answer

Platform investing focuses on the foundational technologies that enable multiple therapeutic applications, rather than betting on individual drugs. Like investing in cloud infrastructure that powers thousands of apps, platform biotech investing targets delivery mechanisms that could power dozens of future therapies across different medical areas.

Question 4

LNP patent holders investing risks?

Accepted Answer

Patent litigation remains unpredictable, and not every delivery technology will prove as valuable as LNPs. The biotech sector experiences dramatic price swings, patents eventually expire, and regulatory changes could impact commercial viability. Additionally, patent challenges could erode competitive advantages that drive licensing revenue.

Question 5

How to invest in drug delivery patent companies?

Accepted Answer

You can invest in companies holding valuable drug delivery patents through platforms like Nemo, which offers commission-free investing and fractional shares starting from £1. The LNP Patent Holders thematic basket provides diversified exposure to multiple delivery technology companies without betting on single therapeutic programmes.

Question 6

Best LNP patent holder stocks 2025?

Accepted Answer

Key companies include Moderna Inc. (MRNA), whose entire mRNA business model depends on LNP delivery technology, BioNTech SE (BNTX), which uses LNPs for COVID vaccines and cancer therapies, and Intellia Therapeutics Inc. (NTLA), which relies on lipid nanoparticles to deliver CRISPR gene-editing tools.

Question 7

Are drug delivery patents more valuable than drugs?

Accepted Answer

The Moderna settlement suggests delivery patents could be extraordinarily valuable—potentially more so than individual drugs. Delivery technology often applies across multiple therapeutic areas, enabling cancer treatments, genetic therapies, and vaccines simultaneously, making these patents potentially more valuable than drug-specific intellectual property.

Question 8

Why are pharmaceutical companies buying delivery tech patents?

Accepted Answer

Big pharma is recognising that delivery technology represents a critical chokepoint. Rather than risk billion-pound settlement demands like Moderna faced, companies are acquiring delivery technology firms outright or negotiating comprehensive licensing agreements upfront to secure their therapeutic supply chains.

Question 9

When will LNP patent licensing boom peak?

Accepted Answer

As advanced therapies move from laboratory to clinic, demand for sophisticated delivery systems is intensifying. The pharmaceutical industry is beginning a broader reassessment of patent values, with investment banks scrambling to revalue biotech patent portfolios following Moderna's landmark settlement precedent.

Question 10

What makes LNP patents different from drug patents?

Accepted Answer

Unlike drug-specific patents, LNP delivery technology applies across multiple therapeutic areas—from mRNA vaccines to gene therapy and cancer immunotherapy. This versatility means a single delivery platform might enable dozens of different treatments, potentially generating licensing revenue from various pharmaceutical applications simultaneously.

Question 11

Can I buy fractional shares of LNP patent holder companies?

Accepted Answer

Yes, through Nemo's regulated platform you can access LNP patent holder investments with fractional shares starting from just £1. The platform offers commission-free trading, AI-driven research, and SIPC protection up to $500,000, making sophisticated biotech patent investing accessible to individual investors.

Patent Goldmine: LNP Technology Licensing Deals Could Reshape Biotech Fortunes

Patent Goldmine: LNP Technology Licensing Deals Could Reshape Biotech Fortunes

Summary

Forget the Miracle Cure, Mind the Delivery Van

The Unseen Engine of Profit

A New Angle for Clever Money

Summary

Forget the Miracle Cure, Mind the Delivery Van

The Unseen Engine of Profit

A New Angle for Clever Money

Deep Dive

Market & Opportunity

Key Companies

Primary Risk Factors

Growth Catalysts

So investieren Sie in diese Chance

Häufig gestellte Fragen

Aktuelle Analysen

SpaceX's Cell Tower Push Could Upend Satellite Phone Rivals

Leaked Data, Lost Confidence: Moderna's Melanoma Stumble

Why Western Digital's Blowout Quarter Is a Storage Wake-Up Call

Tesla's Q3 Surprise: Deliveries Rebound, Margins Take the Hit

Meta's $25bn Verdict Hands Rivals a Rare Opening

Aktuelle Analysen

SpaceX's Cell Tower Push Could Upend Satellite Phone Rivals

Leaked Data, Lost Confidence: Moderna's Melanoma Stumble

Why Western Digital's Blowout Quarter Is a Storage Wake-Up Call

Tesla's Q3 Surprise: Deliveries Rebound, Margins Take the Hit

Meta's $25bn Verdict Hands Rivals a Rare Opening

SpaceX's Cell Tower Push Could Upend Satellite Phone Rivals

Leaked Data, Lost Confidence: Moderna's Melanoma Stumble

Why Western Digital's Blowout Quarter Is a Storage Wake-Up Call

Tesla's Q3 Surprise: Deliveries Rebound, Margins Take the Hit

Meta's $25bn Verdict Hands Rivals a Rare Opening

SpaceX's Cell Tower Push Could Upend Satellite Phone Rivals

Leaked Data, Lost Confidence: Moderna's Melanoma Stumble

Why Western Digital's Blowout Quarter Is a Storage Wake-Up Call

Tesla's Q3 Surprise: Deliveries Rebound, Margins Take the Hit

Meta's $25bn Verdict Hands Rivals a Rare Opening